Skip to main content
. Author manuscript; available in PMC: 2024 Aug 1.
Published in final edited form as: J Med Chem. 2019 Jun 25;62(13):6175–6189. doi: 10.1021/acs.jmedchem.9b00428

Figure 9. Effects of combination treatment of hrGALNS with ezetimibe or pranlukast on the reduction of lysosome size in MPS IVA patient fibroblasts.

Figure 9.

Co-administration of hrGALNS produced in the yeast P. pastoris and the pharmacological chaperones ezetimibe and pranlukast decreased the size of the lysosomes to WT levels. Cells were treated for 72 h with hrGALNS in the presence or absence of ezetimibe or pranlukast. The cells were stained with LysoTracker Red DND-99 dye and the images (9 images/well) were acquired using the IN Cell Analyzer 2200 imaging system. Results are presented as cell intensity normalized to the wild-type fluorescence level (dotted lines). All assays were performed in triplicate (ANOVA Sidak t test ** p < 0.01, *** p < 0.001, **** p < 0.0001). Scale bar: 100 μm.